Loading stock data…
Personalis (PSNL)
$16.60-0.60 (-3.49%)
Market ClosedLast close Sep 8
Personalis, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Personalis, Inc. in the Healthcare sector is trading at $16.60 with a market capitalization of $1.0B. Wall Street consensus targets $15.44 (4 analysts), implying a -7.0% move over the next 12 months. The stock is currently near its 52-week high of $18.89, remaining 67.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -7.0% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.47M↓ | $17.34M↑ | $14.49M↓ | $17.20M↓ | $20.61M |
| Gross Profit | $281,000↓ | $1.90M↓ | $1.91M↓ | $4.76M↓ | $7.21M |
| Operating Income | -$32.16M↓ | -$25.27M↓ | -$23.29M↓ | -$21.80M↓ | -$17.70M |
| Net Income | -$30.03M↓ | -$23.81M↓ | -$21.65M↓ | -$20.06M↓ | -$15.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.51%
Volume
Today's trading volume
2.55M
Recent News
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.
Piper Sandler Lifts Tempus AI to Overweight at $76
Personalis holders receive Tempus shares worth $16.25 each under the pending merger
Tempus AI shares rise 2.7% following analyst actions
Tempus AI (NASDAQ:TEM) shares rose 2. 7% in pre-market trading following analyst actions from Piper Sandler and Canaccord Genuity as investors assessed the company’s pending acquisition of Personalis.
Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?
Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]
Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.
Personalis (PSNL) has demonstrated exceptional momentum, gaining nearly 250% over the past year. Shares recently set a new 3-year high. PSNL stock maintains a 100% “Buy” technical opinion from Barchart. Despite strong price appreciation, PSNL remains unprofitable and highly speculative, with mixed analyst sentiment and significant short interest. Today’s Featured...